Sarcoma, Endometrial Stromal: Clinical Trials

22 trials for Sarcoma, Endometrial Stromal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 2 recruiting, 1 terminated, 1 unknown. 16 Phase 2, 4 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Completed 13, Recruiting 2, Unknown 1
Phase 34Completed 3, Terminated 1
Phase 12Completed 2

Follow Sarcoma, Endometrial Stromal: new trials by email Literature Review of Sarcoma, Endometrial Stromal trials Research Report on Sarcoma, Endometrial Stromal

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Elacestrant - Uterine Sarcoma, Uterine Leiomyosarcoma
Phase 2RecruitingDana-Farber Cancer Institute302026-03-252026-05-22
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma
Phase 2RecruitingHRYZ Biotech Co.1482024-02-212025-07-24
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
Selinexor - Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)
Phase 1CompletedUniversity Health Network, Toronto562021-03-292025-05-29
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
Fulvestrant - Endometrial Stromal Sarcoma, Adenosarcoma of Uterus
Phase 2CompletedFrederic Amant172019-03-132024-05-28
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram - Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Phase 2CompletedNovartis Pharmaceuticals592014-08-012016-12-05
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Trebananib - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Phase 2CompletedGynecologic Oncology Group352011-06-062018-02-23
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
cyproheptadine hydrochloride, placebo - Cancer
Phase 3TerminatedUniversity of South Florida222010-06-012015-07-02
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma
Phase 2CompletedNational Cancer Institute (NCI)172008-02-012018-06-29
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
BI 2536, high performance liquid chromatography, mass spectrometry - Breast Cancer, Endometrial Cancer
Phase 2CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC762007-07-012013-10-07
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
sunitinib malate - Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Phase 2CompletedMemorial Sloan Kettering Cancer Center532007-04-012016-01-20
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
perifosine - Endometrial Cancer, Sarcoma
Phase 2CompletedNCIC Clinical Trials Group172003-06-092023-08-04
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Imatinib mesylate - Life Threatening Diseases
Phase 2CompletedNovartis Pharmaceuticals1852001-02-012016-11-18
Thalidomide in Treating Patients With Gynecologic Sarcomas
thalidomide - Endometrial Cancer, Sarcoma
Phase 2CompletedNew York University Cancer Institute2000-09-012013-06-21
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
imatinib mesylate - Endometrial Cancer, Gastrointestinal Stromal Tumor
Phase 1 / Phase 2CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC912000-08-012012-09-24
Chemotherapy in Treating Patients With Sarcoma of the Uterus
pegylated liposomal doxorubicin hydrochloride - Endometrial Cancer, Sarcoma
Phase 2CompletedGynecologic Oncology Group2000-05-012013-06-10
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
temozolomide - Endometrial Cancer, Ovarian Cancer
Phase 2UnknownHerbert Irving Comprehensive Cancer Center251998-09-012014-01-06
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
paclitaxel, pegylated liposomal doxorubicin hydrochloride - Endometrial Cancer, Fallopian Tube Cancer
Phase 2CompletedNYU Langone Health1997-03-012016-03-11
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3401996-04-012012-07-11
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3501995-02-012014-08-08
Collecting Tumor Samples From Patients With Gynecological Tumors
Laboratory Biomarker Analysis - Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
CompletedGynecologic Oncology Group2751992-06-012016-10-28

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Sarcoma (16)  ·  Endometrial Neoplasms (13)  ·  Leiomyosarcoma (12)  ·  Liposarcoma (12)  ·  Fibrosarcoma (11)  ·  Hemangiosarcoma (11)  ·  Neurofibrosarcoma (11)  ·  Histiocytoma, Malignant Fibrous (10)  ·  Sarcoma, Synovial (10)  ·  Ovarian Neoplasms (9)  ·  Malignant mesenchymal tumor (8)  ·  Rhabdomyosarcoma (8)  ·  Hemangiopericytoma, Malignant (7)  ·  Sarcoma, Alveolar Soft Part (7)

Broader conditions

Endometrial Stromal Tumors (22)  ·  Female Urogenital Diseases (22)  ·  Female Urogenital Diseases and Pregnancy Complications (22)  ·  Genital Diseases (22)  ·  Genital Diseases, Female (22)  ·  Genital Neoplasms, Female (22)  ·  Neoplasms by Histologic Type (22)  ·  Neoplasms, Complex and Mixed (22)  ·  Neoplasms, Connective and Soft Tissue (22)  ·  Urogenital Diseases (22)  ·  Urogenital Neoplasms (22)  ·  Uterine Diseases (22)  ·  Uterine Neoplasms (22)  ·  Neoplasms (21)  ·  Neoplasms by Site (17)

Interventions

Doxorubicin (3)  ·  Ifosfamide (3)  ·  Filgrastim (2)  ·  Imatinib Mesylate (2)  ·  Radiotherapy (2)  ·  BI 2536 (1)  ·  Biopsy (1)  ·  Chemotherapy, Adjuvant (1)  ·  Chromatography, High Pressure Liquid (1)  ·  Cyproheptadine (1)  ·  Fulvestrant (1)  ·  High-Energy Shock Waves (1)  ·  Injections (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Mass Spectrometry (1)

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC (6)  ·  Gynecologic Oncology Group (3)  ·  Novartis Pharmaceuticals (2)  ·  Dana-Farber Cancer Institute (1)  ·  Frederic Amant (1)  ·  HRYZ Biotech Co. (1)  ·  Herbert Irving Comprehensive Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  NCIC Clinical Trials Group (1)  ·  NYU Langone Health (1)  ·  National Cancer Institute (NCI) (1)  ·  New York University Cancer Institute (1)  ·  University Health Network, Toronto (1)  ·  University of South Florida (1)

Countries

United States (11)  ·  Canada (6)  ·  Belgium (5)  ·  Netherlands (4)  ·  France (3)  ·  Italy (3)  ·  United Kingdom (3)  ·  Denmark (2)  ·  Germany (2)  ·  Slovakia (2)  ·  Spain (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  Austria (1)  ·  China (1)

Top investigators

A.N. Van Geel, MD (1)  ·  Albiruni Razak, M.D. (1)  ·  Axel Le Cesne, MD (1)  ·  Elizabeth A. Eisenhauer, MD (1)  ·  Franco M. Muggia, MD (1)  ·  Gavin C.E. Stuart, MD (1)  ·  Gregory P. Sutton, MD (1)  ·  Jacob Verweij, MD, PhD (1)  ·  Jeffrey P. Krischer, PhD (1)  ·  Kathleen Moore (1)  ·  Laurence H. Baker, DO, FACOI (1)  ·  Margaret von Mehren (1)  ·  Mary L. Keohan, MD (1)  ·  Michael Cibull (1)

Results publications

PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 15721421, PMID 16528479, PMID 18378136, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20471824, PMID 22954508

NIH funding

U10CA180868 (2), 2017 (1), N01CM62203 (1), P30CA008748 (1), U10CA027469 (1), U10CA081920 (1)